Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases

European Journal of Cancer

Volumn 43, Issue 5, 2007, Pages 867-876

  Brekelmans, C T M ^a   Tilanus Linthorst, M M A ^a   Seynaeve, C ^a   vd Ouweland, A ^a   Menke Pluymers, M B E ^a   Bartels, C C M ^a   Kriege, M ^a   van Geel, A N ^a   Burger, C W ^a   Eggermont, A M M ^a   Meijers Heijboer, H ^a   Klijn, J G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BRCA1; BRCA2; Breast cancer; Hereditary; Non BRCA1 2; Prognostic factors; Survival

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA DETERMINATION; FAMILIAL CANCER; FEMALE; HEALTH CENTER; HISTOLOGY; HUMAN; LONGEVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; STATISTICAL ANALYSIS; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEDIGREE; PROGNOSIS;

EID: 33847668823     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.12.009     Document Type: Article

References (33)

1. Peto J., Collins N., Barfoot R., et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 91 (1999) 943-949
2. Serova O.M., Mazoyer S., Puget N., et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?. Am J Hum Genet 60 (1997) 486-495
3. Phillips K.A. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18 (2000) 107S-112S
4. Lakhani S.R., Jacquemier J., Sloan J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90 15 (1998) 1138-1145
5. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 (2004) 665-676
6. Phillips K.A., Andrulis I.L., and Goodwin P.J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. J Clin Oncol 17 (1999) 3653-3663
7. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17 (2006) 391-400
8. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 17 (1999) 3396-3402
9. Agnarsson B.A., Jonasson J.G., Bjornsdottir I.B., Barkardóttir R.B., Egilsson V., and Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 47 (1998) 121-127
10. Hedenfalk I., Duggan D., Chen Y., et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 344 (2001) 539-548
11. Honrado E., Osorio A., Palacios J., et al. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol 23 (2005) 7503-7511
12. Verhoog L.C., Berns E.M.J.J., Brekelmans C.T.M., Seynaeve C., Meijers-Heijboer E.J., and Klijn J.G.M. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J Clin Oncol 18 (2000) 119s-124s
13. Loman N., Johannsson O., Bendahl P., et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer 36 (2000) 1365-1373
14. Eerola H., Vahteristo P., Sarantaus L., et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. IJC 93 (2001) 368-372
15. El-Tamer M.B., Russo D., Mansukani M., et al. Survival and recurrence following breast cancer in BRCA1& 2 mutation carriers. Ann Surg Oncol 10 (2003) S33
16. Lakhani S.R., Gusterson B.A., Jacquemier J., et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1, BRCA2. Clin Cancer Res 6 (2000) 782-789
17. The CHEK2-breast cancer consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet 2002;31:55-9.
18. de Bock G.H., Schutte M., Krol-Warmerdam E.M., et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet 41 (2004) 731-735
19. Tilanus-Linthorst M.M., Bartels K.C., Alves C., et al. Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients. Breast Cancer Res Treat 95 (2006) 117-123
20. van der Hout A.H., van den Ouweland A., van der L., et al. A DGGE system for comprehensieve mutation screening of BRCA1 and BRCA2. Application in a Dutch cancer clinic setting. Human Mutat 27 (2006) 654-666
21. Hogervorst F., Cornelis R.S., Bout M., et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 10 (1995) 208-212
22. Petrij-Bosch A., Peelen T., van Vliet M., et al. Large genomic deletions in BRCA1 as major founder mutations among dutch breast cancer families. Nat Genet 17 (1997) 341-345
23. Lynch B.J., Holden J.A., Buys S.S., Neuhausen S.L., and Gaffney D.K. Pathobiologic characteristics of hereditary breast cancer. Human Pathol 29 (1998) 1140-1144
24. Sensi E., Tancredi M., Aretini P., et al. p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 82 (2003) 1-9
25. Noguchi S., Kasugai T., Miki Y., Fukutomi T., Emi M., and Nomizu T. Clinicopathological analysis of BRCA1- or BRCA2- associated hereditary breast carcinoma in Japanese women. Ca 85 10 (1999) 2200-2205
26. Armes J.E., Egan A.J., Southey M.C., et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Ca 83 (1998) 2335-2345
27. Subramaniam D.S., and Isaacs C. Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6 (2005) 147-159
28. Eerola H., Heikkila P., Tamminen A., Aittomaki K., Blomqvist C., and Nevanlinna H. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7 (2005) R465-R469
29. Foulkes W.D., Metcalfe K., Sun P., et al. Estrogen receptor status in BRCA1 and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10 (2004) 2029-2034
30. Colditz G.A., Rosner B.A., Chen W.Y., Holmes M.D., and Hankinson S.E. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96 (2004) 218-228
31. Osin P., Gusterson B.A., Philp E., et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. EJC 34 (1998) 1683-1686
32. Metcalfe K.A., Lynch H.T., Ghadirian P., et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96 (2005) 222-226
33. Kirova Y.M., Stoppa-Lyonnet D., Savignoni A., et al. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 41 (2005) 2304-2311